Current Document Type: HighlightsVideoPage CLL Minimal Residual Disease After Venetoclax and Rituximab Therapy - JADPRO

Watch More Highlights

Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to know about the findings of the MURANO study, which analyzed patients with relapsed or refractory chronic lymphocytic leukemia who had enduring undetectable minimal residual disease after receiving fixed-duration treatment with venetoclax and rituximab (Abstract 125).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.